A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC | |
Huang, J.; Yang, J. -; Fang, J.; Shu, Y.; Chang, J.; Chen, G.; He, J.; Li, W.; Liu, X.; Yang, N. | |
刊名 | JOURNAL OF THORACIC ONCOLOGY |
2017 | |
卷号 | 12期号:11 |
ISSN号 | 1556-0864 |
URL标识 | 查看原文 |
语种 | 英语 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/3539409 |
专题 | 吉林大学白求恩第一医院 |
推荐引用方式 GB/T 7714 | Huang, J.,Yang, J. -,Fang, J.,et al. A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC[J]. JOURNAL OF THORACIC ONCOLOGY,2017,12(11). |
APA | Huang, J..,Yang, J. -.,Fang, J..,Shu, Y..,Chang, J..,...&Wu, Y..(2017).A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC.JOURNAL OF THORACIC ONCOLOGY,12(11). |
MLA | Huang, J.,et al."A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC".JOURNAL OF THORACIC ONCOLOGY 12.11(2017). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论